Open AccessA Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience
Author(s) -
McKee Megan J.,
Keith Kevin,
Deal Allison M.,
Garrett Amy L.,
Wheless Amy A.,
Green Rebecca L.,
Benbow Julie M.,
Dees E. Claire,
Carey Lisa A.,
Ewend Matthew G.,
Anders Carey K.,
Zagar Timothy M.
Publication year - 2016
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2015-0328
Subject(s) - medicine , breast cancer , brain metastasis , radiosurgery , metastatic breast cancer , population , oncology , cancer , radiation therapy , metastasis , environmental health
Background. Breast cancer brain metastasis (BCBM) confers a poor prognosis and is unusual in requiring multidisciplinary care in the metastatic setting. The University of North Carolina at Chapel Hill (UNC‐CH) has created a BCBM clinic to provide medical and radiation oncology, neurosurgical, and supportive services to this complex patient population. We describe organization and design of the clinic as well as characteristics, treatments, and outcomes of the patients seen in its first 3 years. Methods. Clinical and demographic data were collected from patients in a prospectively maintained database. Descriptive statistics are reported as percentages and means. The Kaplan‐Meier method was used to estimate time‐to‐event outcomes. Results. Sixty‐five patients were seen between January 2012 and January 2015. At the time of presentation to the BCBM clinic, most patients (74%) had multiple (≥2) brain metastases and had received prior systemic (77%) and whole‐brain radiation therapy and/or central nervous system stereotactic radiosurgery (65%) in the metastatic setting. Seventy‐eight percent returned for a follow‐up visit; 32% were enrolled in a clinical trial. Median time from diagnosis of brain metastasis to death was 2.11 years (95% confidence interval [CI] 1.31–2.47) for all patients, 1.15 years (95% CI 0.4–2.43) for triple‐negative breast cancer, 1.31 years (95% CI 0.51–2.52) for hormone receptor‐positive/HER2− breast cancer, and 3.03 years (95% CI lower limit 1.94, upper limit not estimable) for HER2+ breast cancer ( p = .0037). Conclusion. Patients with BCBM have unique and complex needs that require input from several oncologic disciplines. The development of the UNC‐CH multidisciplinary BCBM clinic is a model that can be adapted at other centers to provide coordinated care for patients with a challenging and complex disease. Implications for Practice: Patients with breast cancer brain metastases often require unique multidisciplinary care to meet the numerous and uncommon challenges associated with their conditions. Here, the development and characteristics of a clinic designed specifically to provide for the multidisciplinary needs of patients with breast cancer brain metastases are described. This clinic may serve as a model for other institutions interested in creating specialty clinics with similar objectives.